Download

Download Full Text (437 KB)

Keywords

Acute kidney injury

Disciplines

Anesthesiology

Description

Acute kidney injury (AKI) is a common, life-threatening complication in patients with sepsis and septic shock.→ Approximately one-half of patients with sepsis experience an AKI.4 → One-third of all acute kidney injuries are related to sepsis.4 → Sepsis-associated AKI raises in-hospital mortality eightfold and the risk of chronic kidney disease development threefold.1,2,3. Early identification of AKI could save time and resources, lower costs, improve patient outcomes. Therefore, a biomarker for earlier AKI detection in patients with sepsis would serve an outstanding role in health care.In the setting of bacterial infection, an upregulation of innate immune system gene transcription and translation causes the surge in procalcitonin (PCT). This can be observed within 2-4 hours of an immune response, peaking within 12-24 hours.5.Procalcitonin is often used to monitor both the presence and resolution of bacterial infection.6 PCT algorithms are also a biomarker for preventing antibiotic overconsumption, and allow reassurance during antibiotic cessation.7 Due to the utility of procalcitonin in monitoring bacterial sepsis incidence and resolution, the authors hypothesize that its concentration in serum could serve as a biomarker for AKI risk stratification in patients suspected of bacterial sepsis.

Publication Date

5-2025

Comments

The Embark Capstone Colloquium at the Oakland University William Beaumont School of Medicine, Rochester Hills, MI, May, 2025.

Procalcitonin as a biomarker of acute kidney injury in patients with suspected bacterial sepsis in the acute care setting

Share

COinS